Sino Biological,Inc. (SHE:301047)
73.10
-0.73 (-0.99%)
At close: May 12, 2026
Sino Biological,Inc. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 157.25 | 147.74 | 121.93 | 260.13 | 302.96 | 720.01 |
Depreciation & Amortization | 90.98 | 90.98 | 90.97 | 69.21 | 37.61 | 25.8 |
Other Amortization | 10.29 | 10.29 | 9.73 | 8.71 | 6.2 | 10.17 |
Loss (Gain) From Sale of Assets | -0.54 | -0.54 | 0.35 | -0.05 | -0.21 | 0.01 |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 15.51 |
Loss (Gain) From Sale of Investments | -84.58 | -84.58 | -90.2 | -100.32 | -54.15 | -74.32 |
Provision & Write-off of Bad Debts | 6.89 | 6.89 | 8.26 | 11.05 | 0.26 | - |
Other Operating Activities | 27.86 | 6.75 | 6.26 | 15.8 | -16.2 | -9.13 |
Change in Accounts Receivable | -26.14 | -26.14 | -20.79 | 83.15 | 21.01 | 26.66 |
Change in Inventory | -20.47 | -20.47 | 14.39 | -21.94 | -32.98 | -17.73 |
Change in Accounts Payable | 11.95 | 11.95 | -9.72 | 16.66 | 8.06 | -74.04 |
Change in Other Net Operating Assets | 0.44 | 0.44 | 0.77 | 2.7 | 1.8 | 4.34 |
Operating Cash Flow | 176.81 | 146.19 | 113.73 | 322.56 | 249.39 | 642.62 |
Operating Cash Flow Growth | 57.23% | 28.54% | -64.74% | 29.34% | -61.19% | -41.20% |
Capital Expenditures | -115.44 | -101.05 | -69.95 | -1,043 | -156.06 | -47.9 |
Sale of Property, Plant & Equipment | 0.43 | 0.67 | - | 0.03 | - | - |
Cash Acquisitions | -50.35 | -50.35 | -285.05 | - | - | - |
Investment in Securities | 404.15 | 506.27 | -167.18 | -220.75 | -19.51 | -2,541 |
Other Investing Activities | 72.85 | 76.7 | 86.28 | 76.1 | 111.42 | 40.31 |
Investing Cash Flow | 311.65 | 432.24 | -435.91 | -1,188 | -64.15 | -2,549 |
Long-Term Debt Repaid | - | -31.09 | -30.88 | -31.35 | -24.11 | -28.3 |
Total Debt Repaid | -31.09 | -31.09 | -30.88 | -31.35 | -24.11 | -28.3 |
Net Debt Issued (Repaid) | -31.09 | -31.09 | -30.88 | -31.35 | -24.11 | -28.3 |
Issuance of Common Stock | - | - | - | - | - | 4,741 |
Repurchase of Common Stock | - | - | -453.14 | - | - | - |
Common Dividends Paid | -608.18 | -608.18 | -255.52 | -258.4 | -680 | - |
Other Financing Activities | 1.49 | -0.12 | -0.1 | -0.22 | -0.16 | - |
Financing Cash Flow | -637.78 | -639.39 | -739.64 | -289.97 | -704.27 | 4,712 |
Foreign Exchange Rate Adjustments | -1.96 | 0.62 | -0.41 | -6.13 | 5.13 | 0.92 |
Net Cash Flow | -151.28 | -60.35 | -1,062 | -1,162 | -513.89 | 2,807 |
Free Cash Flow | 61.38 | 45.14 | 43.78 | -720.8 | 93.34 | 594.72 |
Free Cash Flow Growth | 31.46% | 3.10% | - | - | -84.31% | -44.66% |
Free Cash Flow Margin | 8.43% | 6.45% | 7.13% | -111.51% | 16.24% | 61.61% |
Free Cash Flow Per Share | 0.51 | 0.37 | 0.34 | -5.58 | 0.82 | 5.52 |
Cash Income Tax Paid | 47.5 | 54.15 | 45.53 | -0.06 | 88.22 | 208.51 |
Levered Free Cash Flow | -34.35 | -26.11 | 72.52 | -871.24 | 28.46 | 364.82 |
Unlevered Free Cash Flow | -32.42 | -24.18 | 75.01 | -868.91 | 30.2 | 366.07 |
Change in Working Capital | -31.34 | -31.34 | -33.57 | 58.04 | -27.06 | -45.42 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.